title: Mitomycin C.
abstract: In conclusion, recent work has highlighted the fact that NSCLCs have elevated levels of NQO1 activity and that such an increase represents an excellent target for therapeutic exploitation. The 5-year survival rate seen with lung cancer is dismal and there is a high number of cancer deaths associated with this disease each year. This renders the design of molecules that can be activated by NQO1 (such as MeDZQ or CB 10-200) an extremely important and urgent issue.
authors.affiliation: Cancer Research Group, Central Research Pfizer Inc., Groton, CT.
authors.forename: N W
authors.initials: NW
authors.lastname: Gibson
authors.forename: D
authors.initials: D
authors.lastname: Ross
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000201:enzymology*; D015195:Drug Design; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology*; D016685:Mitomycin / Q000378:metabolism*; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000378:metabolism*; D010084:Oxidation-Reduction; D011809:Quinones / Q000378:metabolism; D013379:Substrate Specificity
chemical_list: D011809:Quinones; D016685:Mitomycin; D016660:NAD(P)H Dehydrogenase (Quinone)